Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.46 |
| ▸ | CTSK | P43235 | 9/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213287 | 1.00 | CTSS (0.46) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL7291726 | 0.88 | JAK3 (0.51) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL8382498 | 0.88 | JAK3 (0.51) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL14923490 | 0.88 | JAK3 (0.51) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL5438237 | 0.83 | CTSK (0.55) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL18354057 | 0.83 | GAA (0.44) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL13413129 | 0.83 | CTSK (0.55) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL13662491 | 0.83 | CYP2D6 (0.43) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL14842208 | 0.82 | CTSK (0.43) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL14496975 | 0.82 | CTSK (0.43) | CTSSCTSKCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772277-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ESRRA, ESRRB, ESR2 | CTSS 4792/4885CTSK 4764/4885CTSL 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.